Governance Cybin Inc.

HELP

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
4.150 ^USD	-6.32%		-8.79%	-49.27%

Apr. 30	Cybin Inc. will Change its Name to Helus Pharma	CI
Apr. 28	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health	CI

Executive Committee: Cybin Inc.

Manager

Positions heldSince

Eric So

51 year

Chief Executive Officer	2026-04-19
Founder	2016-10-12
President	2020-11-04

Greg Cavers

56 year

Director of Finance/CFO

2020-11-04

Erica Olson

Comptroller/Controller/Auditor

2021-04-30

Jill Conwell

Human Resources Officer

2026-03-11

Atul Mahableshwarkar

Chief Tech/Sci/R&D Officer

2024-06-10

Allison House-Gecewicz

Chief Tech/Sci/R&D Officer

2022-03-31

Naomi Morris

General Counsel

Ryan Richardson

Chief Tech/Sci/R&D Officer

Amir Inamdar

Chief Tech/Sci/R&D Officer

2021-09-30

Geoff Varty

Chief Tech/Sci/R&D Officer

2021-09-30

Robert Mino

General Counsel

2021-09-30

Gabriel Fahel

51 year

Investor Relations Contact	-
General Counsel	2020-10-31
Corporate Secretary	2020-10-31

Aaron Bartlone

59 year

Chief Operating Officer

2023-06-30

Alex Nivorozhkin

66 year

Chief Tech/Sci/R&D Officer

2020-11-30

Lori Challenger

Chief Administrative Officer	2021-09-30
Compliance Officer	2021-09-30

Ken Kramer

Chief Tech/Sci/R&D Officer

2026-04-15

Composition of the Board of Directors: Cybin Inc.

Director

CommitteesSince

Eric So

51 year

Compensation Committee	2020-11-04
Governance Committee	2020-11-04
Nominating Committee	2020-11-04

Theresa Firestone

70 year

Audit Committee	2024-01-28
Compensation Committee	2021-08-15
Governance Committee	2021-08-15
Nominating Committee	2021-08-15
Compensation Committee Chair	2024-01-28
HR Committee Chair	2024-01-28
Governance Committee Chair	2024-01-28
Nominating Committee Chair	2024-01-28

Eric Hoskins

65 year

Audit Committee	2020-11-04
Governance Committee Chair	2023-06-28
Nominating Committee Chair	2023-06-28
Audit Committee Chair	2023-06-28
Compensation Committee Chair	2023-06-28

Mark Lawson

54 year

Audit Committee	2020-06-25
Compensation Committee	2020-11-04
Governance Committee	2020-11-04
Nominating Committee	2020-11-04
Audit Committee Chair	2020-11-04

Freda Lewis-Hall

71 year

Governance Committee	2021-09-30
Nominating Committee	2021-09-30
Audit Committee	2019-06-30
HR Committee	2019-06-30

Grant Froese

64 year

Audit Committee	2020-11-04
Compensation Committee Chair	2020-11-04

Paul Glavine

37 year

Director/Board Member

2016-10-12

Latest Appointments: Cybin Inc.

Apr. 23	Helus Pharma Announces Scientific Advisory Board Appointments	CI
Apr. 20	Helus Pharma Announces CEO Changes Effective April 20, 2026	CI
Apr. 16	Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026	CI
Mar. 12	Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026	CI
Feb. 24	Helus Pharma appoints former Pfizer chief medical officer to board of directors	RE
Feb. 24	Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee	CI
Feb. 10	Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026	CI

More news

Former Officers and Directors: Cybin Inc.

Insider

Positions held

SinceUntil

Michael Cola

Chief Executive Officer

2026-02-09

2026-04-19

Douglas Drysdale

Chief Executive Officer

2020-07-31

2025-09-01

Greene Brett

Chief Tech/Sci/R&D Officer

2020-11-30

2023-06-04

Michael Palfreyman

Chief Tech/Sci/R&D Officer

2023-06-04

Leah Gibson

Investor Relations Contact

2021-11-03

2023-05-31

Alexander Belser

Chief Tech/Sci/R&D Officer

2020-09-30

2023-04-30

Joan M. Krakowsky

Chief Tech/Sci/R&D Officer

2023-03-31

Jacqueline Poriadjian-Asch

Investor Relations Contact	-	-
Sales & Marketing	-	2021-12-30

John Kanakis

Founder	2016-10-12	2021-11-03
Investor Relations Contact	2021-03-29	2021-11-03
Public Communications Contact	-	2021-11-03
Corporate Officer/Principal	2021-11-03	2021-11-03

Cameron Carvalho

Corporate Officer/Principal

2021-04-30

Jukka Kalervo Karjalainen

Chief Tech/Sci/R&D Officer

2018-12-31

2021-01-31

Sara Brittany Somerset

Public Communications Contact

Lorenzo Gordon

Corporate Officer/Principal

James Andrews

Corporate Officer/Principal

Liz Galic

Chief Operating Officer

Harry Nijjar

Director of Finance/CFO

Age distribution of managers

Parity Men Women

Male	20
Female	6

Of which Executive Committee

Male	11
Female	5

Of which Directors

Male	6
Female	1

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Employees

Sector

Biotechnology & Medical Research

More about the company